PDF(Pubmed)
Abstract：
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
摘要：
氟轻松（FAc）玻璃体内植入物（Iluvien®）是一种皮质类固醇植入物，适用于先前接受常规治疗但没有良好反应的患者的糖尿病性黄斑水肿（DMO）的治疗，非感染性后葡萄膜炎,并作为视网膜静脉阻塞继发的黄斑水肿的标签外治疗。FAc是不可生物降解的0.19mg玻璃体内植入物,其被设计为以每天约0.2mcg的速率在3年内释放FAc。这篇综述的目的是描述Iluvien的特殊药理特性，并显示有关其治疗上述视网膜疾病的有效性和安全性的最重要的临床试验和现实世界研究的结果。
